A Phase 2/3 interventional study of Cesemat in Marijuana Smoking, sponsored by University of British Columbia. Completed at 1 site in Canada. Open to participants aged 19 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-02-17.
Sponsored by University of British Columbia · Phase 2/3, Interventional, and Treatment
Safety of Nabilone in reducing marijuana craving
Randomized double blind trial into the safety and efficacy of Cesemat for the treatment of marijuana use
517 studies on the registry are indexed under Marijuana Abuse; 114 are open to participants now.
This study's planned enrollment of 35 is below the median of 60 across 421 interventional studies indexed under Marijuana Abuse.
Browse Marijuana Abuse studies →University of British Columbia is the lead sponsor of 1,309 studies on the registry; 253 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Drug: Cesemat
1 mg capsule per day for 21 days
Also known as: Nabilone
Safety and tolerability to Nabilone
Marijuana craving questionnaire
This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of British Columbia